Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 4/20 | 0.86 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | DNM1 | Q05193 | 7/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1684241 | 1.00 | SLC22A1 (0.86) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| SCHEMBL2870114 | 1.00 | SLC22A1 (0.86) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| SCHEMBL2870319 | 1.00 | SLC22A1 (0.86) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Iodide SCHEMBL5089300 | 0.97 | SLC22A1 (0.80) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Bromide SCHEMBL5088473 | 0.97 | SLC22A1 (0.80) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Hydrochloric Acid SCHEMBL5087658 | 0.97 | SLC22A1 (0.80) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Water SCHEMBL3308155 | 0.97 | SLC22A1 (0.80) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Hydrochloric Acid SCHEMBL5091328 | 0.97 | SLC22A1 (0.80) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Water SCHEMBL3304024 | 0.97 | SLC22A1 (0.80) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL5718772 | 0.97 | SLC22A1 (0.80) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251310-A1 | Hydrophosphorylation of Phosphonous Acid Derivatives for Flame Retardants | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-10-13 | — | — | US | claimed |
| US-20140005037-A1 | TRIMER CATALYST ADDITIVES FOR IMPROVING FOAM PROCESSABILITY | EVONIK OPERATIONS GMBH (DE) | 2014-01-02 | — | — | US | disclosed |
| US-20130276666-A1 | PHASE CHANGE INK COMPOSITIONS AND SULFONATED COMPOUNDS FOR USE IN THE SAME | XEROX CORPORATION (US) | 2013-10-24 | — | — | US | disclosed |
| US-8545612-B1 | Phase change ink compositions and sulfonated compounds for use in the same | XEROX CORPORATION (US) | 2013-10-01 | — | — | US | disclosed |
| EP-1352902-A1 | Process for producing Epsilon-Caprolactam and catalyst for the production | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-10-15 | — | — | EP | disclosed |
| US-5595715-A | FROM TETRAMETHYLAMMONIUM HYDROXIDE, SILICA, AND HYDROLYZALEALUMINUM COMPOUND | MOBIL OIL CORPORATION (US) | 1997-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251310-A1 | Hydrophosphorylation of Phosphonous Acid Derivatives for Flame Retardants | NR1H3, NR1H2, NR1H4 | SLC22A1 864/4885SLC22A2 858/4885ALDH1A1 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.